Expired Canadian patentCanada
Combined therapeutical treatment of hyperproliferative diseases
CA 2209771 C · Owner: Aventis Pharma S.A. · Inventors: Tocque, Bruno
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A medicinal combination of one or more nucleic acids that at least partially inhibit oncogenic cell signalling pathways and a therapeutic anticancer agent, for use simultaneous separate or over a period of time to treat hyperproliferative diseases.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 12, 1996 and granted January 3, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 12, 2016.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 12, 2018.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledJanuary 12, 1996
GrantedJanuary 3, 2012
Term endedJanuary 12, 2016
Patent numberCA 2209771 C
Classification (IPC)A61K48/00 +2 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.